Caladrius Biosciences Inc (CLBS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Caladrius Biosciences Inc (CLBS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3481
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a cell therapy service provider. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. It offers products to target type one diabetes mellitus, used to treat imbalance in an immune system, to treat condition caused by ischemia, and to repair and regenerate cardiovascular tissue. Caladrius provide technology that helps cells by enabling the body to rebalance irregularities. The company offers T regulatory technology and CD34 technology. It offers services such as product and process development, engineering and automation, GMP manufacturing, cell and tissue processing, storage and distribution, and expert consulting and regulatory support. Caladrius serves biotechnology, pharmaceutical and medical product companies, and academic research institutions. The company operates in Basking Ridge, Irvine and New York, the US. Caladrius is headquartered in Basking Ridge, New Jersey, the US.

Caladrius Biosciences Inc (CLBS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
Kiadis Pharma Enters into Agreement with PCT 15
Caladrius Biosciences Enters into Development Agreement with Sanford Research 16
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 17
NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 18
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 19
Licensing Agreements 21
Caladrius Biosciences Enters into Licensing Agreement with Shire 21
Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 22
Hitachi Chemical Enters into Licensing Agreement with Progenitor Cell Therapy 23
AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 24
SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 25
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 29
Equity Offering 30
Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 30
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 31
Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 33
Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 35
Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 37
Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 38
NeoStem Raises USD29 Million in Public Offering of Shares 39
NeoStem to Raise USD30 Million in Private Placement of Shares 40
NeoStem Completes Public Offering Of Shares For US$40.25 Million 41
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 42
NeoStem Completes Public Offering Of Shares For US$11.5 Million 43
NeoStem Completes Private Placement Of Common Stock For US$3 Million 44
NeoStem Completes Public Offering Of Units For US$6.8 Million 46
Acquisition 48
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 48
Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 50
NeoStem Completes Acquisition Of California Stem Cell 51
NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For US$12 Million 53
Caladrius Biosciences Inc – Key Competitors 54
Caladrius Biosciences Inc – Key Employees 55
Caladrius Biosciences Inc – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
Financial Announcements 57
Aug 09, 2018: Caladrius Biosciences reports 2018 second quarter and first six months financial results 57
May 10, 2018: Caladrius Biosciences Reports 2018 First Quarter Financial Results 59
Mar 22, 2018: Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results 60
Nov 09, 2017: Caladrius Biosciences Reports 2017 Third Quarter Results 62
Aug 10, 2017: Caladrius Biosciences Reports 2017 Second Quarter Results 64
May 15, 2017: Caladrius Biosciences Announces 2017 First Quarter Financial Results 66
Mar 17, 2017: Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results 68
Other Significant Developments 70
Jul 02, 2018: Dr. Marilyn Glassberg Presents Findings on Stem Cell Treatments for Lung Diseases 70
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Kiadis Pharma Enters into Agreement with PCT 15
Caladrius Biosciences Enters into Development Agreement with Sanford Research 16
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 17
NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 18
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 19
Caladrius Biosciences Enters into Licensing Agreement with Shire 21
Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 22
Hitachi Chemical Enters into Licensing Agreement with Progenitor Cell Therapy 23
AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 24
SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 25
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 29
Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 30
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 31
Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 33
Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 35
Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 37
Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 38
NeoStem Raises USD29 Million in Public Offering of Shares 39
NeoStem to Raise USD30 Million in Private Placement of Shares 40
NeoStem Completes Public Offering Of Shares For US$40.25 Million 41
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 42
NeoStem Completes Public Offering Of Shares For US$11.5 Million 43
NeoStem Completes Private Placement Of Common Stock For US$3 Million 44
NeoStem Completes Public Offering Of Units For US$6.8 Million 46
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 48
Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 50
NeoStem Completes Acquisition Of California Stem Cell 51
NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For US$12 Million 53
Caladrius Biosciences Inc, Key Competitors 54
Caladrius Biosciences Inc, Key Employees 55
Caladrius Biosciences Inc, Other Locations 56
Caladrius Biosciences Inc, Subsidiaries 56

List of Figures
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Caladrius Biosciences Inc (CLBS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PTT Exploration and Production Public Co Ltd (PTTEP):企業の財務・戦略的SWOT分析
    PTT Exploration and Production Public Co Ltd (PTTEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • First Financial Bancorp:企業の戦略・SWOT・財務情報
    First Financial Bancorp - Strategy, SWOT and Corporate Finance Report Summary First Financial Bancorp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BP Australia Group Pty Ltd:企業の戦略的SWOT分析
    BP Australia Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Mother Dairy Fruit & Vegetable Pvt. Ltd.:企業の戦略的SWOT分析
    Mother Dairy Fruit & Vegetable Pvt. Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Handok Inc (002390)-医療機器分野:企業M&A・提携分析
    Summary Handok Inc (Handok), formerly known as Handok Pharmaceuticals Co Ltd, is a pharmaceutical and health care company which develops, manufactures and distributes healthcare solutions. The company develops and provides pharmaceutical products including prescription drugs, OTC drugs, medical devi …
  • Vibra Healthcare LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Vibra Healthcare LLC (Vibra) is a healthcare service provider that provides short-term rehabilitation, long-term care, skilled nursing and respite care services. The organization develops and acquires medical rehabilitation hospitals and long term acute care hospitals. It offers services suc …
  • Polaris Industries Inc (PII):企業の財務・戦略的SWOT分析
    Polaris Industries Inc (PII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Red Rock Resorts, Inc. (RRR):企業の財務・戦略的SWOT分析
    Red Rock Resorts, Inc. (RRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Amarin Corp Plc (AMRN):企業の財務・戦略的SWOT分析
    Amarin Corp Plc (AMRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • HNI Corp (HNI):企業の財務・戦略的SWOT分析
    HNI Corp (HNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Emera Inc.:企業の戦略・SWOT・財務分析
    Emera Inc. - Strategy, SWOT and Corporate Finance Report Summary Emera Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Biosynex SA (ALBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Biosynex SA (Biosynex), formerly All Diag Sarl is an in-vitro diagnostic company that manufactures, research, and develops rapid diagnostic tests. The company offers rapid diagnostic kits for diagnostic applications; and designing, self-measurement, and distributing thermometers. It offers t …
  • CSE Global Limited (544):石油・ガス:M&Aディール及び事業提携情報
    Summary CSE Global Limited (CSE) is a technology company offering process control systems and integrated plant communication systems. It’s process control systems offers emergency shutdown systems, process shutdown systems, integrated control & safety systems and fire and gas detection systems, well …
  • Okinawa Electric Power Company Incorporated (9511):企業の財務・戦略的SWOT分析
    Okinawa Electric Power Company Incorporated (9511) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Tech Mahindra Limited:企業の戦略・SWOT・財務分析
    Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report Summary Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Illinois Municipal Electric Agency:企業の戦略的SWOT分析
    Illinois Municipal Electric Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Veikkaus Oy:企業の戦略的SWOT分析
    Veikkaus Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Verisk Analytics, Inc.:企業の戦略・SWOT・財務情報
    Verisk Analytics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Verisk Analytics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Duraloy Technologies Inc:企業の戦略的SWOT分析
    Duraloy Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Iridex Corp (IRIX):企業の財務・戦略的SWOT分析
    Summary Iridex Corp (Iridex) operates as a medical device company that manufactures and distributes laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. The company offers products such as lasers, laser delivery devices, glauco …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆